EORTC Gynecological Cancer Group (GCG) Meeting
|
|
|
- Anne Skinner
- 10 years ago
- Views:
Transcription
1 EORTC Gynecological Cancer Group (GCG) Meeting VENUE : HOTEL SANTA CATALINA. LEÓN Y CASTILLO, LAS PALMAS DE GRAN CANARIA RECOMMENDED HOTEL: SANTA CATALINA (HTTP :// (ALTERNATIVE HOTEL : EXE CANTERAS, PORTUGAL, 68) LAS PALMAS DE GRAN CANARIA (CANARY ISLANDS, SPAIN) DATES : FRIDAY 17TH AND SATURDAY 18TH OCTOBER 2014 Friday 17 th October 2014 Time slot Topic / Title of presentation Name of speakers/room Young investigator meeting (Part I) Open meeting Coffee break Special session. EORTC GCG Immunotherapy platform. Introduction. Dr. Emad Shash. Specta as a model (15 ) Cellular based immunotherapy for ovarian cancer. Center of Experimental Therapeutics (Lausanne). Prof. Lana Kandalaft. (35 ) Therapeutic vaccines on gynecological cancer. Dr. Suzy Scholl (20 ) Vaccines and immunotherapy research at Nijmegen.Dr. Nelleke Ottevanger (15 ) Overview on HPV trials and an update on recent advances on HPV research. Prof. Gemma Kenter: (20 ) Launch TBA EORTC GCG General Assembly and Business meeting Welcome and information on the meeting A. Casado, Mario Federico, Pedro Lara
2 Ovarian Tumor Site Committee. P. Ottevanger (Chair), I. Vergote, A. Casado, D. Katsaros, I. Boere, L. Vidal, A. Wolfer Reserve: A. Westermann. Report on accepted EORTC HQ and GCG trials (30-35 ) EORTC (part II): randomized phase II trial of pazopanib and weekly paclitaxel / carboplatin in recurrent platin resistant and refractory ovarian carcinoma (EORTC PI: I. Vergote). Dr. N. Ottevanger, Prof. I. Vergote, Dr. Anneke Westermann, Dr. Anita Wolfer, Dr. A. Casado DGCG/NCRI (GCIG/ENGOT proposal). EORTC Vargatef (Nintedanib, BIBF1120) in recurrent clear cell ovarian and endometrial cancer (EORTC GCG PI: A. Westermann). Endorsed by the EORTC Ex Co on 14th June New proposals under discussion (35-40 ) New proposals (immunotherapy) from Lausanne. Dr. A. Wolfer (15-20 ). New proposals (N. Ottevanger) (15 ) Endometrial Tumor Site Committee. A. Casado or N. Ottevanger on behalf of F. Amant (Chair), R. Verheijen, A. Nordin, J van der Velden, M. Romeo, F. Herrera, F. Mota (tbc) Report on accepted EORTC HQ and GCG trials Dr. Antonio Casado, Dr. Nelleke Ottevanger, Dr. Nick Reed, Prof. Ignace Vergote, Dr. Emad Shash, Dr. R. Verheijen/E. Van Dorst GOG-UC1009/EORTC : A phase III randomized trial of gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited high grade uterine leiomyosarcoma (GOG PI: Martee Hensley, EORTC GCG PI: N. Ottevanger). Endorsed by PRC on 3 rd January 2012 (15 ). P. Ottevanger, E. Shash. EORTC EORTC/CRUK/NCI. A randomized phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUS) after stabilization or response to chemotherapy following surgery or in metastatic first line treatment. (EORTC PI: I. Ray Coquard. EORTC GCG PI: N. Reed). Endorsed by PRC on 14 th March 2012 and last amendment s approval on 31 st January 2013 (12 ). N. Reed, E. Shash. EORTC Efficacy of aromatase inhibitors in primary advanced or recurrent endometrial stromal sarcoma: a phase II trial (EORTC GCG PI: F. Amant). Endorsed by PRC on 27 th July 2012 (15 ). Amendments to protocol approved in the IRCI meeting in June 2013, but re-discussions took place at the last IRCI meeting (June 2014). New proposals (A. Casado, All) Coffee break
3 Cervix Tumor Site Committee. G. Kenter (Chair), A. Sadozye, L. van Doorn, Elzbieta van der Steen, A. Ferrero, M. Huizing, M. Snidiaki (tbc) REPORT from the new ROG-EORTC GCG GYNECOLOGIC WORKING PARTY (Dr. Fernanda Herrera, Dr. Laura Vidal) (10-15 ). Dr. Gemma Kenter, Dr. Suzy Scholl, Dr. Fernanda Herrera, Dr. E. Shash, Ellen Peeters, Prof. Roman Rouzier, Dr. A. Ferrero New proposals New proposals on immunotherapy approaches. A Phase II/III Clinical Trial of Chemo-radiotherapy in combination with VGX-3100 and INO-9012 in Patients with Locally Advanced Cervical Cancer. EORTC Dr. Fernanda Herrera (CHUV) (15 ). Endorsed by the PRC on 16 th May 2014 New proposals from Curie: A randomized phase II study of HPV therapeutic vaccine Transgene TG4001 combined with anti-pd-1 antibody for patients with cervical cancer (S. Scholl, Curie) (15-20 ) New proposals and Potential collaboration with the ROG Vulvar cancer proposal/s. Prof. Roman Rouzier. Dr. Manuel Rodrigues and Dr. Johanna Wassermann (Curie) (20) (TBC) The "elderly and cervix project" (Dr. Johanna Wassermann) (TBC). Auditorium Reports on ongoing/recently closed trials EORTC neoadjuvant cervix trial: Update on the status of the status of EORTC G. Kenter (15 ) Update on TR combined proposal (TRAC review) and paraffin blocks collections (G. Kenter, N. Ottevanger, E. Shash and E. Peeters) EORTC 55092: Phase Ib of pazopanib and weekly paclitaxel / carboplatin in recurrent platin resistant and refractory ovarian carcinoma (EORTC PI: I. Vergote) (15 ) ENGOT-EN2-DGCG / EORTC study. A phase III trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer. (DGCG PI: M. Raza Mirza. EORTC PI: F. Amant). Endorsed by PRC on 5 th March Amendment 4 endorsed by PRC in February 2014 (15 ). A. Casado/E. Shash on behalf of F. Amant Auditorium General Assembly and Business meeting (A. Casado) EORTC HQ report (June 2014) (A. Casado, E. Shash) (10 ) SAC review 2013 and EORTC GCG scientific strategy (A. Casado, P. Ottevanger ) (15 ) EORTC GCG future meetings (A. Casado) (5 )
4 New applications and reapplications/changes in personnel (P. Ottevanger) (10 ) Financial report (I. Vergote) (15 ) Elections of new EORTC GCG officers for : Chair, Secretary and Treasurer (35-40 ) Dinner Hotel Santa Catalina TBA Saturday 18 th October Young investigator meeting. Part II. Voting and selection of new proposals Report on survivorships issues -An update on the overview of this program. EORTC HQ personnel (E. Shash, C. Coens) - Psychological distress related to the FU visits - patients preferences re time schedule and examinations - patients concerns - sexual health issues Dr. Eleonora van Dorst, E. Shash, C. Coens, A. Casado, N. Ottevanger -Fertility issues, sexuality and early menopause. -Lymphedema New proposals (E. van Dorst) Coffee break Translational Research Subcommittee (Suzy Scholl, P. Berns) ESGO/ENGOT INTEGRATE initiative (A. Casado) (5 ) OMICs PH5 (Suzy Scholl) Discussions on BioRaids participation (Dr. Suzy Scholl) Targeted therapies in cervical cancer. Dr. Manuel Rodrigues proposal (Curie) (15 ) (TBC) Surgical Subcommittee (E. Van Dorst) -A proposal for endometrial cancer PROTOCOL COMMITTEE (A. Casado /I. Vergote) Summary of discussions Presentations to re-discuss or clarify specific points if needed Voting for new proposals (TBC) Report on GCIG and ENGOT -GCIG activities and future meetings GCIG brainstorming meeting on cervix cancer on 6 th Nov in Melbourne) 5 th OCCC (Tokyo, 2015) E. van Dorst, P. Coronado, I. Zapardiel, R. Rouzier PC members * A. Casado, N. Ottevanger, I. Vergote, E. Shash
5 GCIG report (A. Casado, N. Ottevanger) -ENGOT phase I/II and TR platforms (I. Vergote, A. Casado) -ENGOT GCA activities (A. Casado, I. Boere) -ENGOT report (A. Casado, N. Ottevanger, E. Sash) Official scientific meeting closes Next EORTC GCG meeting: EGAM 12th 13th March, 2015, Brussels (Crowne Plaza Hotel) * PC members: I. Vergote (Leuven, Chair PC and Treasurer), A. Casado (Madrid, Chair EORTC GCG), F. Amant (Leuven, Chair Corpus TSC), G. Kenter (Amsterdam, Chair Cervix TSC), F. Herrera (Chair Radiotherapy subcommittee), E. van Dorst (Surgery subcommittee), 5 top accrual D. Katsaros (Torino), N.S. Reed, (Glasgow, Scotland), Ko van der Velden (Amsterdam), F. Landoni, (Milano), N. Ottevanger Secretary and Chair OVTS (Nijmegen), P. Debruyne (Czak), Emad Shash (Coordinating Research Physician EORTC HQ), Suzy Scholl (TR subcommittee Chair), P. Berns (TR subcommittee co-chair) Corneel Coens (EORTC HQ statistician)
Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
Cellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
How To Compare The Effects Of A Hysterectomy And A Hysterectomy
A RANDOMIZED TRIAL COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN PATIENTS WITH LOW RISK EARLY STAGE CERVICAL CANCER A Gynecologic Cancer
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)
Under the Auspices of Organized by 10th International Symposium Advanced Ovarian Cancer: Optimal Therapy. Update Valencia, Spain, 6th March 2015 Directors Andrés Poveda Fundación Instituto Valenciano de
PRIMARY TREATMENT CLINICAL PRESENTATION INITIAL EVALUATION. Conclude procedure with/without lymph node dissection
INITIAL EVALUATION History and Physical CXR Pathology review 1 Labs Consider CA125, and pre-operative imaging of abdomen and pelvis Screen for Lynch Syndrome by family history or molecular testing CLINICAL
Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
Avastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
Gynäkologische Onkologie-Klinische Studien
Gynäkologische Onkologie-Klinische Studien Breast cancer A randomized, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer
GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE
GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE Personal Information Date of birth July 2, 1953 Place of birth Torino, Italy Office address Department of Oncology S. Luigi Gonzaga Hospital, Oncology
CA 125 definitions agreed by GCIG November 2005
CA 125 definitions agreed by GCIG November 2005 The GCIG has agreed criteria for defining response and progression of ovarian carcinoma which use the serum marker CA 125, and the situations where these
CLINICAL ONCOLOGY MASTERCLASS IN. 25-29 April 2015 São Paulo, Brazil. Chairs: Scientific Co-ordinators: ESO - LATIN-AMERICAN PROGRAMME
ESO - LATIN-AMERICAN PROGRAMME MASTERCLASS IN CLINICAL ONCOLOGY 25-29 April 2015 São Paulo, Brazil Chairs: N. Pavlidis, GR - R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F. Cardoso, PT FOREWORD
What is a clinical trial? An introduction for patients and families
What is a clinical trial? An introduction for patients and families Introduction Life expectancy in Europe in the first decade of this century has continued to rise. We owe this fortunate development to
Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
Wednesday, February 24 th, 2016
List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University
ONCOLOGY NURSING 7 TH ESO-EONS MASTERCLASS IN. 8-13 March 2014 Ermatingen (Lake Constance) Switzerland MASTERCLASS
MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 7 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 8-13 March 2014 Ermatingen
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers
Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers Emile Voest, MD, PhD Department of Medical Oncology University Medical Center Utrecht the Netherlands 4e Nascholing Targeted Therapy April
The Role of Laparoscopy in Endometrial Cancer
The Role of Laparoscopy in Endometrial Cancer Prof. Dr. Tugan BEŞE İstanbul University, Cerrahpaşa Medical Faculty Gynecologic Oncology Department Surgical staging in Endometrial Cancer Laparoscopic surgery
ADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT
te: Consider Clinical Trials as treatment options for eligible patients. Referral to a center with both pediatric oncology and orthopedic surgery is essential. CLINICAL EVALUATION This practice algorithm
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens
Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.
Promises and challenges of developing new drugs in oncology
3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San
Surgical Staging of Endometrial Cancer
Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging
Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer
Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
Avastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
How To Treat A Uterine Sarcoma
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas
Scientific Programme
Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico
Cytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
Invasive Cervical Cancer. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Invasive Cervical Cancer Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Etiology Human Papilloma Virus (HPV): Detected in 99.7% of cervical cancers Cancer
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
ductal carcinoma in situ (DCIS)
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding
Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
The Role of Clinical Practice Guidelines, Survivorship Care Plans, and Inter-sectoral Care in Cancer Rehabilitation
The Role of Clinical Practice Guidelines, Survivorship Care Plans, and Inter-sectoral Care in Cancer Rehabilitation Prof. Eva Grunfeld, MD, DPhil, FCFP Ontario Institute for Cancer Research/Cancer Care
U.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
New strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Wednesday Oct 7th, 2015 Congress Center (Hörsaal 1 3) Marien Hospital Herne Accreditation by the Medical Chamber
SAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
Promises and challenges of developing new drugs in oncology
3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San
Osteosarcoma: treatment beyond surgery
Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma
Level 1. Nutrition & Lifestyle Oncology Certificate
Level 1 Nutrition & Lifestyle Oncology Certificate ONE MODULE 1 A Cancer Diagnosis Learn what cancer is; how/why it develops; diagnostic tests; inflammatory/ hormonal connections; 5 most important steps
Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015
Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating
REVIEW ARTICLE. Key Words: CA 125, Ovarian cancer, Response, Progression, RECIST, Clinical trials
REVIEW ARTICLE Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) Gordon John Sampson Rustin,
Navigating GIST. The Life Raft Group June 12, 2008
Navigating GIST Clinical Trials The Life Raft Group June 12, 2008 Some observations: Annually, only 3% of adult patients participate in cancer clinical trials. Lara et. al; Evaluation of factors affecting
Endometrial Cancer Treatment
Endometrial Cancer Treatment January 2006 By Shelly Smits, RHIT, CCS, CTR mary by Ian Thompson, MD Data Source: Cancer registry information on uterine cancer diagnosed 1/1/2000 to 12/31/2004. Reason for
Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
Breast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
Prostate Cancer Studies
Prostate Cancer Studies STUDIES CURRENTLY RECRUITING MDV3100-14 A multinational, Phase 3, Randomized, Double- Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastic
Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
THE FUTURE OF CLINICAL TRIALS: NEW MODEL TO ENHANCE EFFICIENCY. Jeff Allen, PhD Executive Director Friends of Cancer Research
THE FUTURE OF CLINICAL TRIALS: NEW MODEL TO ENHANCE EFFICIENCY Jeff Allen, PhD Executive Director Friends of Cancer Research Current Challenges Each potential new therapy is typically tested independently
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
Moving forward, where are we with Clinical Trials?
Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where
Treatment options for recurrent ovarian cancer
Treatment options for recurrent ovarian cancer There are a number of treatment options for women with recurrent ovarian cancer. Chemotherapy is the treatment most commonly offered and on occasion, surgery
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
Fulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
Medical Marijuana Use in Patients with History of SCCHN Treated with Radiotherapy
HEALTH SERVICES RESEARCH Assessment the Impact of Real-time Tumor Tracking & Reduced Planning Target Volume Margins on Quality-of-Life in Prostate Cancer Patients Treatment with Intensity Modulated Radiotherapy
Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
Info-pack for participants Young Entrepreneurs and Fundraising Training Course (#) (v. 08 21.01.2015)
Info-pack for participants Young Entrepreneurs and Fundraising Training Course (#) (v. 08 21.01.2015) Friday 13/03/2015 - Wednesday 18/03/2015. Gran Canaria (Canary Islands Spain) Dear participants, Welcome
What is neuroendocrine cervical cancer?
Key Points: 1. Neuroendocrine cancer of the uterine cervix is a rare and aggressive disease. 2. Treatment for neuroendocrine cervical cancer is usually more intensive than that for most other types of
WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region
WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region April 2016 27-30 Santiago - Chile Hotel Diego de Almagro San Pío X 2530, Providencia, Santiago. INFORMATION www.lungcancerworkshop.cl
Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer. Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK
Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK Overview of Presentation This presentation will discuss the management
Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation
PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS and PM1183 in small cell lung cancer, soft tissue sarcoma, and mesothelioma Compelling clinical activity of PM1183 in
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
Facing Hysterectomy? Learn why da Vinci Surgery may be your best treatment option for early stage gynecologic cancer
Facing Hysterectomy? Learn why da Vinci Surgery may be your best treatment option for early stage gynecologic cancer The Condition: Early Stage Gynecologic Cancer A wide variety of gynecologic cancers
1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision
RADIATION THERAPY FOR GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT GYNECOLOGIC CANCERS Gynecologic cancers
A Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
Ask Us About Clinical Trials
Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing
Wednesday, February 24 th, 2016
List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University
GOOD CLINICAL PRACTICE PROGRAM. Workshop 2006 DC THERA. November 27th 28th 2006, Dorint Hotel Erlangen, Germany
DC THERA Dendritic Cells & New Immunotherapies EU Sixth Framework Programme Life Science, Genomics and Biotechnology for Health DC-THERA Dendritic Cells & New Immunotherapies Network of Excellence, Project
Regional Young Investigator SIC meeting. 5-6 March 2015
Regional Young Investigator SIC meeting 5-6 March 2015 Aula Magna A - Università Magna Graecia di Catanzaro - Campus Universitario S. Venuta Viale Europa, loc. Germaneto - Catanzaro Invited speakers: Rita
Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is
New Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
Avastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
COMPENDIA TRANSPARENCY TRACKING FORM. Ovarian cancer, recurrent
COMPENDIA TRANPARENCY TRACKING FORM DRUG: Pemetrexed INDICATION: Ovarian cancer, recurrent COMPENDIA TRANPARENCY REQUIREMENT 1 Provide criteria used to evaluate/prioritize the request (therapy) 2 Disclose